SEARCH

SEARCH BY CITATION

References

  • 1
    Hanto DW, Shelton MW, Simmons RL. Malignancies after organ transplantation. In: PaulLC, SolezK eds. Organ Transplantation: Long Term Results. New York : Marcel Dekker, 1992: 319351.
  • 2
    Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology 2003; 185: 229240.
  • 3
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222230.
  • 4
    McCann J. Lowering immune suppression drugs post-transplant may cut cancer risk. J Natl Cancer Inst 2003; 95: 848849.
  • 5
    Diethelm AG, Deierhoi MH, Hudson SL et al. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann Surg 1995; 221: 446457.
  • 6
    Kehinde EO, Petermann A, Morgan JD et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994; 81: 985986.
  • 7
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 15141516.
  • 8
    Penn I. Cyclosporine and oncogenesis. Mt Sinai J Med 1987; 54: 460464.
  • 9
    Penn I. Neoplastic complications of transplantation. Semin Respir Infect 1993; 8: 233239.
  • 10
    Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994; 8: 388395.
  • 11
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant receipts. N Engl J Med 1990; 323: 17231728.
  • 12
    Muti G, Cantoni S, Oreste P et al. Cooperative Study Group on PTLDs. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 6777.
  • 13
    Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748755.
  • 14
    Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278298.
  • 15
    European MMF Co-operative Study Group. Placebo-controlled study of MMF combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 13211325.
  • 16
    Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225232.
  • 17
    Tricontinental Mycophenolate Mofetil Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 19291937.
  • 18
    Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000; 11: 4548.
  • 19
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.
  • 20
    Frei U, Brunkhorst R, Schindler R et al. Present status of kidney transplantation. Clin Nephrol 1992; 38: S46S52.
  • 21
    Albrechtsen D, Leivestad T, Fauchald P, Flatmark A, Sodal G, Thorsby E. Results of the National Kidney Transplantation Program in Norway. Clin Transpl 1992; 6: 207213.
  • 22
    Bentdal OH, Leivestad T, Fauchald P et al. The national kidney transplant program in Norway still results in unchanged waiting lists. Clin Transpl 1998; 12: 221228.
  • 23
    Candinas D, Schlumpf R, Rothlin MA, Binswanger U, Largiader F. Thirty-two years of renal transplantation in Zurich. Clin Transpl 1996; 10: 241247.
  • 24
    Graeme R. Transplantation. In: DisneyAPS ed. ANZDATA Registry Report 2000. Adelaide , South Australia : Australia and New Zealand Dialysis and Transplant Registry, 2000.
  • 25
    Ward RA, Brier ME. Retrospective analyses of large medical databases. What do they tell us? J Am Soc Nephrol 1999; 10: 429432.